Publish in this journal
Journal Information
Vol. 14. Num. 1.January - February 2018
Pages 1-62
Share
Share
Download PDF
More article options
ePub
Visits
360
Vol. 14. Num. 1.January - February 2018
Pages 1-62
Original Article
DOI: 10.1016/j.reumae.2016.09.004
Direct medical costs and their predictors in the EMAR-II cohort: “Variability in the management of rheumatoid arthritis and spondyloarthritis in Spain”
Costes médicos directos y sus predictores en la cohorte “Variabilidad en el manejo de la artritis reumatoide y las espondiloartritis en España”
Visits
360
Leticia Leona,b,
Corresponding author
lleon.hcsc@salud.madrid.org

Corresponding author.
, Lydia Abasoloa, Benjamin Fernandez-Gutierreza, Juan Angel Jovera, Cesar Hernandez-Garciac
a Servicio de Reumatología, Hospital Clínico San Carlos, Madrid, Spain
b Universidad Camilo José Cela, Madrid, Spain
c Agencia Española de Medicamentos y Productos Sanitarios, Madrid, Spain
This item has received
360
Visits
Article information
Statistics
Figures (1)
Tables (3)
Table 1. Multiple Linear Regression Analysis of the Direct Medical Costs in the Population of Rheumatoid Arthritis Patients.
Table 2. Multiple Linear Regression Analysis of the Direct Medical Costs in Patients Who did not Receive Biological Agents.
Table 3. Multiple Linear Regression Analysis Of The Direct Medical Costs In Patients Who Received Biological Agents.
Show moreShow less
Abstract
Objective

To analyze the resource utilization in rheumatoid arthritis (RA) patients and predictive factors in and patients treated with biological drugs and biologic-naïve.

Methods

A cross-sectional study was performed in a sample including all regions and hospitals throughout the country. Sociodemographic data, disease activity parameters and treatment data were obtained. Resource utilization for two years of study was recorded and we made costs imputation. Correlation analyzes were performed on all RA patients and those treated with biological and biological naïve, to estimate the differences in resource utilization. Factors associated with increased resources utilization (costs) attending to treatment was analyzed by linear regression models.

Results

We included 1.095 RA patients, 26% male, mean age of 62±14 years. Mean of direct medical costs per patient was €24,291±€45,382. Excluding biological drugs, the average cost per patient was €3742±€3711. After adjustment, factors associated with direct medical costs for all RA patients were biologic drugs (P=.02) and disease activity (P=.004). In the biologic-naïve group, the predictor of direct medical costs was comorbidity (P<.001). In the biologic treatment group predictors were follow-up length of the disease (P=.04), age (P=.02) and disease activity (P=.007).

Conclusion

Our data show a remarkable economic impact of RA. It is important to identify and estimate the economic impact of the disease, compare data from other geographic samples and to develop improvement strategies to reduce these costs and increase the quality of care.

Keywords:
Cost
Rheumatoid arthritis
Economic impact
National cohort
Resumen
Objetivo

Estimar los costes médicos directos en los pacientes con artritis reumatoide (AR) y los factores predictores en los pacientes tratados con fármacos biológicos y sin biológicos.

Métodos

Se realizó un estudio transversal en una muestra incluyendo pacientes de toda la geografía nacional. Se obtuvieron datos sociodemográficos y de tratamiento. Se registró la utilización de recursos para los 2 años de estudio y se hizo imputación de costes. Se realizaron análisis de correlación en todos los pacientes con AR y en los tratados con y sin biológicos, para estimar las diferencias entre los grupos. Los predictores de costes se analizaron mediante modelos de regresión lineal.

Resultados

Se incluyeron 1.095 pacientes con AR, el 26% hombres, con una edad media de 62±14 años. La media de los costes médicos directos por paciente fue de 24.291±45.382€. Excluyendo los fármacos biológicos, el coste medio por paciente fue de 3.742±3.711€. Después de ajustar, los factores predictores de costes médicos directos para todos los pacientes con AR fueron los fármacos biológicos (p=0,00), la comorbilidad (p=0,00) y la edad del paciente (p=0,01). En el grupo sin biológicos, los predictores fueron la comorbilidad (p=0,00) y la edad del paciente (p=0,01). En el grupo con biológicos los predictores fueron el sexo del paciente (p=0,03) y la actividad de la enfermedad (p=0,02).

Conclusión

Los datos muestran un notable impacto económico de la AR. Es importante identificar y estimar los factores asociados a mayor coste para desarrollar estrategias de reducción de costes y aumentar la calidad de la atención.

Palabras clave:
Coste
Artritis reumatoide
Impacto económico
Cohorte nacional

Article

These are the options to access the full texts of the publication Reumatología Clínica (English Edition)
Member
If you are member of Sociedad Española de Reumatología (SER) or the Colegio Mexicano de Reumatología (CMR):
Please go to the member area of SER or CMR and log in.
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Reumatología Clínica (English Edition)

Contact
Telephone
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
902 88 87 40
Calls from outside Spain
+34 932 418 800
E-mail
Idiomas
Reumatología Clínica (English Edition)

Subscribe to our Newsletter

Article options
Tools
es en
Política de cookies Cookies policy
Utilizamos cookies propias y de terceros para mejorar nuestros servicios y mostrarle publicidad relacionada con sus preferencias mediante el análisis de sus hábitos de navegación. Si continua navegando, consideramos que acepta su uso. Puede cambiar la configuración u obtener más información aquí. To improve our services and products, we use "cookies" (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?